Eli Lilly
Forbes Global 2000 1876 #71 by revenue · LLY United States Healthcare Drugs & Biotechnology lilly.com
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products.
Forbes Global 2000's description, shown to identify the company. We rate the name, not the business.
- Evocativity EVOC : red
- Personal-name phrase gives no medicine cue
- Brevity BREV : yellow
- 8 letters, 4 syllables. Up to seven letters is green, eight at two syllables too; up to ten yellow, eleven or more red.
- Greppability GREP : green
- Found inside 0 other dictionary words.
- Googlability GOOG : yellow
- Historical personal name offers some competing meaning
- Pronounceability PRON : green
- Familiar names read clearly
- Spellability SPEL : red
- Eli versus Ely and Lilly versus Lily are uncertain
- Verbability VERB : red
- Personal-name pair resists verb use
- Nominology
- 40
- All seven dimensions and .com ownership, weighted as set out on Methodology.
- Fluency
- 80
- Brevity and pronounceability only: the subset with published outcome evidence behind it.
- PG grade
- 3 / 4
- Graham's own four-step ladder.
- Exact .com
- Not owned
- Shape
- phrase
- Length
- 9 chars, 4 syllables
- Distinctiveness
- arbitrary
Watkins SCRATCH flags
- Spelling-challenged
This row is stitched from more than one source. Forbes Global 2000 supplied the company; fortune500 filled ticker.
Rubric version 2026.10.20-1, judged by gpt-6.1-sol (agent).
This scores the name only. See Methodology.
These judged dimensions came from an AI agent working through the judging queue in a chat, on the same rubric the scoring pipeline sends. The agent passed the calibration exam before its work was accepted, and each batch it judged hid two names with known answers as a check. The model is named as the agent reported it.